Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of its drug for Lou Gehrig’s disease, acknowledging it didn't help patients with the deadly neurological condition. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Malaysia Malaysia Latest News, Malaysia Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Why Amylyx is pulling ALS drug Relyvrio from US market after studyThe maker of a drug for Lou Gehrig’s disease that recently failed in a study says it will pull the medicine from the U.S. market. Amylyx Pharmaceuticals said Thursday it will halt marketing in the U.S. and Canada. In March, the drugmaker announced that its drug had failed to show any benefit for patients in a 600-person study.
Source: AP - 🏆 728. / 51 Read more »
Controversial ALS Drug May Be Pulled from Market After Disappointing Trial ResultsFollowing disappointing trial results, the maker of a controversial ALS drug may pull the medication off the market. Amylyx Pharmaceuticals is considering voluntarily withdrawing the drug, Relyvrio/Albrioza, after it failed to help patients in a large follow-up study. The company has decided to pause promotion of the medication and will announce their plans for the drug in the next two months.
Source: MedicineNet - 🏆 575. / 51 Read more »